Dexcom G7 CGM sensor - accessory that makes stacking multiple days easier

By Nora Whitfield, ad hoc news Accessories & Components Desk. Reviewed July 01, 2026, 1:10 AM ET. Details in the imprint.

Dexcom G7 CGM sensor sits on the back of your arm like a slightly raised white pebble, about the size of a nickel, quietly tracking blood glucose for up to 10 days at a time. You feel it for a second when the applicator clicks, then mostly forget it’s there while your phone buzzes with readings.

Smaller sensor, faster warmup

Dexcom G7 is the latest disposable sensor in Dexcom’s continuous glucose monitoring lineup, cleared for use in the US for people with diabetes aged 2 and older. The sensor pairs with a transmitter built into the housing, simplifying what used to be a separate accessory in older Dexcom systems.

The G7 sensor is about 60 percent smaller than the previous G6 sensor, which makes it feel less obtrusive under clothing and reduces the chance of snagging on doorframes or backpack straps. A shorter 30-minute warmup means users start seeing live glucose data sooner after attaching a new sensor.

Flexible wear and smartphone data

In the US, Dexcom positions the G7 sensor for a 10-day wear period, after which users peel it off and apply a fresh sensor with a single-use applicator. The sensor can be worn on the back of the upper arm for adults, and on the upper buttocks for children 2 to 6, giving parents some flexibility in managing sensor placement.

G7 sensors stream real-time glucose readings to compatible iOS and Android devices via Bluetooth, displaying trend arrows, alerts and 24-hour graphs in the Dexcom G7 app. Clinicians like endocrinologist David Ahn have highlighted the value of these sensors for reducing hypoglycemia and improving time-in-range metrics for their patients.

Insurance coverage and pricing

In US pharmacies, Dexcom G7 sensors are sold as boxes of three sensors, each lasting up to 10 days, though pricing can vary widely depending on insurance coverage and pharmacy contracts. Without insurance, reported cash prices for a box often land in the low to mid-hundreds of dollars.

Dexcom has struck agreements with major US pharmacy benefit managers and insurers to make G7 sensors available as a pharmacy benefit, reducing out-of-pocket costs for many users compared with durable medical equipment channels. The company notes that most commercially insured patients in the US now have some coverage for G7 sensors, though copays and deductibles still matter.

Regulatory status and clinical use

The US Food and Drug Administration cleared Dexcom G7 as an integrated continuous glucose monitoring system, meaning the sensor can be used with compatible insulin pumps and digital health tools for automated insulin delivery. That integration helps patients and clinicians fine-tune therapy without constant fingersticks, using G7 sensor data for dosing decisions.

Clinical trials presented by Dexcom suggest G7 sensors maintain performance metrics comparable to or better than G6 sensors, with mean absolute relative difference (MARD) figures in the high single digits around 8 to 9 percent. Endocrinologist Anne Peters has pointed out that such accuracy levels are crucial for building trust in CGM data used to guide insulin dosing.

Everyday experience for US users

From a day-to-day perspective, US users often describe the G7 sensor applicator as a quick, one-click affair, a notable change from earlier multi-step setups. The adhesive patch is designed to survive showers, light swimming and sweat from moderate exercise, though some users report needing overpatches for contact sports.

Walking through a Brooklyn grocery store with a G7 sensor on your arm, the only real reminder is the periodic buzz from your phone when glucose drifts high after a bakery stop. That quiet background presence is part of the appeal for patients like marathon runner and type 1 patient Cody Beals, who rely on CGM data to adjust carb intake in real time.

Context and stock backdrop

Dexcom Inc. positions G7 sensors as the disposable core of its US CGM ecosystem, competing with Abbott’s FreeStyle Libre and Medtronic’s Guardian lines in a growing market for sensor-based diabetes care. Dexcom stock (NASDAQ: DXCM) is listed in USD on Nasdaq and closely watched as CGM adoption expands in the US and abroad.

This article was AI-assisted and editorially reviewed. Product information is provided without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Securities trading carries risks up to total loss.